US OptionsDetailed Quotes
RXRX241206C6500
- 0.75
- -0.05-6.25%
15min DelayClose Dec 4 16:00 ET
0.80High0.68Low
0.80Open0.80Pre Close17 Volume411 Open Interest6.50Strike Price1.27KTurnover123.89%IV1.68%PremiumDec 6, 2024Expiry Date0.63Intrinsic Value100Multiplier2DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.8661Delta0.3477Gamma10.56Leverage Ratio-0.0350Theta0.0003Rho9.15Eff Leverage0.0011Vega
Recursion Pharmaceuticals Stock Discussion
“The evolution of precision and personalized treatment options for oncology patients provide promising alternatives,” says William McKean, MD, Clinical Investigator at START Mountain Region in Salt Lake City, Utah. “We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and look forward to advancing the science of cancer treatment.”
$Recursion Pharmaceuticals (RXRX.US)$
$NVIDIA (NVDA.US)$
Goldman Sachs also pointed out in a previous report that by 2025, investors are expected to shift from AI infrastructure to a broader "t...
No comment yet